MedTrace Logo

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

NCT04810611 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-10-10

No results posted yet for this study

Summary

The purpose of this study was to characterize the safety, tolerability and confirm the dose for select single agents and combinations in patients with lower risk (very low, low, and intermediate risk) MDS.

Conditions

Interventions

DRUG

MBG453

Anti-TIM3 monoclonal antibody

DRUG

NIS793

Anti-TGF-β monoclonal antibody

DRUG

canakinumab

Anti-IL-1β monoclonal antibody

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-18
Primary Completion
2024-04-19
Completion
2024-04-19
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Israel
  • Italy
  • Singapore
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04810611 on ClinicalTrials.gov